NCT07423078 2026-04-13
WOLF
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
8 trialsNCT05533775 2026-04-03
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06052839 2026-02-09
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
University of Pittsburgh
Phase 2 Recruiting
NCT06859775 2025-06-06
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT06670911 2025-02-24
ACCESS-I
Instituto Nacional de Cancer, Brazil
Phase 2 Recruiting
NCT06413992 2024-05-14
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT02889666 2024-04-17
CCODG-NSCLC
Shanghai Jiao Tong University School of Medicine
Phase 1 Recruiting
NCT05983276 2024-02-08
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University
Phase 2 Recruiting